Literature DB >> 19171110

Aspirin and acetaminophen: should they be available over the counter?

Kay Brune1, Burkhard Hinz, Ivan Otterness.   

Abstract

Traditional nonsteroidal anti-inflammatory drugs block cyclooxygenase (COX). They are the most widely used drugs for pain relief. They are indispensable for their effects but are condemned for their adverse drug reactions. Two COX inhibitors, acetaminophen and aspirin, are the most widely used over-the-counter drugs. They have low (but useful) therapeutic activity, but they are endowed with specific risks that are not seen with most other COX inhibitors. Both are lethal if taken in overdose. Each is stigmatized by severe adverse effects. Aspirin results in prolonged inhibition of blood coagulation, and acetaminophen can result in liver toxicity at normal dose and liver failure at higher dose. Both drugs cause many deaths every year. We recommend that the status of both drugs be changed to prescription only. Their continued availability over the counter poses an unacceptable risk to the general population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171110     DOI: 10.1007/s11926-009-0006-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  37 in total

Review 1.  Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.

Authors:  Angel Lanas; James Scheiman
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

2.  Acetaminophen toxicity: changing perceptions on a social/medical issue.

Authors:  William M Lee
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

3.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

Review 4.  The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis.

Authors:  Carla R Scanzello; Neal K Moskowitz; Allan Gibofsky
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

5.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Authors:  J D Bradley; K D Brandt; B P Katz; L A Kalasinski; S I Ryan
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

6.  Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.

Authors:  D W Kaufman; J P Kelly; J E Sheehan; A Laszlo; B E Wiholm; L Alfredsson; R S Koff; S Shapiro
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

Review 7.  Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties.

Authors:  Bela Kis; James A Snipes; David W Busija
Journal:  J Pharmacol Exp Ther       Date:  2005-05-06       Impact factor: 4.030

8.  Non-narcotic analgesic dose and risk of incident hypertension in US women.

Authors:  John P Forman; Meir J Stampfer; Gary C Curhan
Journal:  Hypertension       Date:  2005-08-15       Impact factor: 10.190

9.  Acute renal dysfunction in acetaminophen poisoning.

Authors:  Girish Mour; Donald A Feinfeld; Thomas Caraccio; Michael McGuigan
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

10.  Paracetamol induced hepatotoxicity.

Authors:  S B K Mahadevan; P J McKiernan; P Davies; D A Kelly
Journal:  Arch Dis Child       Date:  2006-03-17       Impact factor: 3.791

View more
  5 in total

1.  From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.

Authors:  Eva Barrenberg; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2017-03-28       Impact factor: 2.953

Review 2.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

3.  FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?

Authors:  Garry G Graham; Richard O Day; Andis Graudins; Anthoulla Mohamudally
Journal:  Inflammopharmacology       Date:  2010-03-07       Impact factor: 4.473

4.  Use of over-the-counter (OTC) drugs and perceptions of OTC drug safety among German adults.

Authors:  E Barrenberg; E Garbe
Journal:  Eur J Clin Pharmacol       Date:  2015-08-25       Impact factor: 2.953

5.  The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.

Authors:  Joseph V Pergolizzi; Robert Taylor; Robert B Raffa
Journal:  Adv Ther       Date:  2015-05-31       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.